DOCSLIB.ORG

The Ocular Hypotensive Effects of Demeclocycline, Tetracycline and Other Tetracycline Derivatives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Ocular Hypotensive Effects of Demeclocycline, Tetracycline and Other Tetracycline Derivatives Investigative Ophthalmology & Visual Science, Vol. 30, No. 7, July 1989 Copyright © Association for Research in Vision and Ophthalmology The Ocular Hypotensive Effects of Demeclocycline, Tetracycline and Other Tetracycline Derivatives Ira Wallace, Theodore Krupin, Richard A. Srone, and Jay Moolchandani Demeclocycline, tetracycline and other tetracycline derivatives lowered intraocular pressure (IOP) in rabbits following intravitreal injection, but the onset of this effect was not evident until 1 or more days after drug administration. Of the drugs tested, demeclocycline was the most active ocular hypotensive agent. Demeclocycline caused a dose-dependent decrease in IOP. The maximum IOP decrease of approximately 12 mm Hg occurred 5 days after intravitreal administration of 0.5 mg, with the effect persisting for over a week. Demeclocycline did not alter tonographically measured aqueous humor outflow facility or episcleral venous pressure. Based on calculated aqueous humor flow rates following 0.2 mg demeclocycline, a 62% decrease in aqueous humor formation occurred 7 days after intravitreal injection. The flow-to-diffusion ratio for ascorbate was reduced 54% 6 days after the intravitreal administration of demeclocycline, a change also consistent with suppression of aqueous humor forma- tion. Anterior chamber aqueous humor protein concentration was increased 6 days after demeclocy- cline administration. No histologic changes were present in the treated eyes by light microscopy. Intravitreal demeclocycline similarly lowered IOP in cats, with the duration of effect lasting up to 20 days. Invest Ophthalmol Vis Sci 30:1594-1598,1989 Possible roles in the regulation of intraocular pres- sopressin.6 The most active tetracycline derivative in sure (IOP) for biologically active peptides, either this regard is demeclocycline, which may even induce those present locally within peptide containing nerve nephrogenic diabetes insipidus.7 Demeclocycline is fibers or those reaching the eye through the blood, an effective therapy for the syndrome of inappropri- remain poorly defined.1 Intravenous administration ate ADH secretion because of this effect.8 of the nanopeptide vasopressin, or antidiuretic hor- In the eye, vasopressin does not stimulate cyclic mone (ADH), stimulates aqueous humor formation AMP production in isolated ciliary processes,9 and and elevates IOP in rabbits,2'3 apparently as the result desmopressin does not elevate aqueous humor cyclic of a direct effect on active sodium transport across the AMP.4 Paradoxically, however, we have found that ciliary epithelium.2 Intravenous desmopressin, a syn- demeclocycline inhibits the IOP rise caused by des- thetic analog of vasopressin, similarly increases mopressin.4 Demeclocycline alone shows no acute aqueous humor formation and raises IOP.4 effect on IOP; but during the course of our studies, we In its antidiuretic action on the kidney, both vaso- observed that demeclocycline has an ocular hypoten- pressin and desmopressin stimulate the production of sive effect developing days after local administration the intracellular second messenger hormone, cyclic to the eye. We therefore studied the direct effects of adenosine 3'5' monophosphate (cyclic AMP), which demeclocycline, tetracycline and other tetracycline initiates a series of events that ultimately decrease derivatives on IOP. urine flow.5 The tetracycline drugs inhibit the vaso- pressin-induced stimulation of cyclic AMP in the kidney and thus block the antidiuretic action of va- Materials and Methods Awake, 2- to 3-kg albino rabbits and 3- to 4-kg cats were restrained in cloth wrappers or in plexiglass From the Glaucoma Service, Department of Ophthalmology, boxes specially designed for each species. Systemic University of Pennsylvania School of Medicine, Scheie Eye Insti- tute, Philadelphia, Pennsylvania. anesthetic agents were not used during any of the Supported by NIH Grants EY-05267, EY-05454, a National experiments. IOP was measured after 0.5% topical Glaucoma Research Grant from the American Health Assistance proparacaine HC1 anesthesia using a Digilab Model Foundation (Dr. Krupin), and the Archie E. Cruthirds Research 30R pneumatonometer (Cambridge, MA) manomet- Fund of the Scheie Eye Institute. rically calibrated for rabbit and cat eyes. Drugs for Submitted for publication: March 24, 1988; accepted December 12, 1988. intravitreal injection were dissolved in filtered (0.22 Reprint requests: Theodore Krupin, MD, Scheie Eye Institute, ^m) distilled water or normal saline. The pH was 51 N. 39th Street, Philadelphia, PA 19104. adjusted with NaOH as close to neutrality as possible 1594 Downloaded from iovs.arvojournals.org on 09/25/2021 No. 7 TETRACYCLINES AND INTRAOCULAR PRESSURE / Wallace er al 1595 without drug precipitation. An acidic solution was required for the 0.2 mg (pH 6.6) and 0.5 and 1.0 mg (pH 6.3) injections. Osmolarity was adjusted with NaCl to between 350 and 360 mOsm. +) >- O) Intravitreal injections were performed after topical 2 I -4 0.5% proparacaine HC1 anesthesia using a 30-gauge o" IE needle on a 0.025 ml Hamilton syringe with a Chaney adaptor. The final volume injected was 0.01 ml, except for the 1.0 mg dose of demeclocycline -8 which required 0.02 ml. In all rabbits, one eye re- 0.01 0.05 0.1 0.2 0.5 1.0 ceived intravitreal drug and the fellow control eye Intravitreal demeclocycline (mg) received an equal volume of intravitreal filtered ster- ile saline with an adjusted pH similar to the drug Fig. 1. Dose-dependent effect of intravitreal demeclocycline on intraocular pressure in rabbits. The change in intraocular pressure solution. In the cats, each animal received a single (IOP) 8 days after intravitreal injection is illustrated. The values uniocular injection of either drug or saline. Except represent [(IOPcontrO| eye) - (IOP,reated eye)] for 8-14 rabbits at each where indicated, the rabbits but not the cats also re- demeclocycline dose. Using t-statistics on the paired differences, ceived 10 mg/kg intraperitoneal indomethacin (40 IOP is significantly reduced following the 0.1 mg (P < 0.05) and the higher (P < 0.001) concentrations of demeclocycline. mg/ml in 1 M Na2CO3) 2 to 3 hr before intravitreal injection. A stable baseline IOP was established both before indomethacin pretreatment and again before chamber (Ch) aqueous humor and in the plasma (Cp). intravitreal drug injection. After drug administration, Assuming that the rate of diffusion remains constant, IOP generally was measured hourly for 6 hr and then this relationship has been employed to measure the every 24 or 48 hr until it returned to baseline. To effects of various agents on the flow rate.12 The pro- control for possible diurnal fluctuations, daily IOP tein concentration of these anterior chamber aqueous readings were recorded between 1 and 3 PM. samples also was measured using Biuret and Folin Aqueous humor dynamics were studied in rabbits phenol reagents (Total Protein Kit No. 690, Sigma following intravitreal injection of 0.2 mg demeclocy- Chemical Co., St. Louis, MO). cline. Seven days after demeclocycline administra- For histopathologic study, three rabbits were sacri- tion in six animals, aqueous humor outflow facility ficed with an overdose of sodium pentobarbital 6 was measured on awake and restrained animals by days after intravitreal injection of 0.2 mg demeclocy- tonography (4 min recordings) using an electronic cline. Both the drug and saline injected eyes were Schiotz tonometer connected to a graph recorder. fixed in formalin, embedded in paraffin, serial-sec- Aqueous humor flow rate was calculated using the tioned in four quadrants, and stained with hematox- Goldmann equation,10 F = (Po - Pv) C; where F ylin/eosin or with Periodic Acid Schiff. = aqueous humor flow rate in /itl/min, Po = intraoc- The effects on IOP of six additional tetracycline ular pressure in mm Hg, Pv = episcleral venous pres- compounds were tested after intravitreal administra- sure in mm Hg, and C = aqueous humor outflow tion of 0.5 mg in rabbits using the same protocol, facility in /xl/min/mm Hg. Episcleral venous pressure except that no indomethacin pretreatment was given. was measured with an episcleral venomanometer in IOP was measured daily in these rabbits for 14 days. six rabbits before and 7 days following intravitreal Intravenous demeclocycline, 40 mg/kg, was ad- demeclocycline. ministered via the marginal ear vein in eleven rabbits. Six days after intravitreal injection of 0.2 mg dem- IOP was measured at 3 hr and 6 hr following injec- eclocycline in another 15 awake rabbits, aqueous tion and then daily for a total of 8 days. humor samples were obtained by posterior and ante- Statistical analysis used the student t-test on paired rior chamber paracentesis after topical 0.5% propara- differences to compare drug- and vehicle-treated eyes caine HC1 anesthesia. These aqueous humor samples within each experimental group and an unpaired t- were placed immediately in 4.0% metaphosphoric test for intergroup analysis. Drug effects are reported acid and titrated with dichlorphenol-indophenol for as mean ± SEM, with P < 0.05 considered signifi- estimation of ascorbate concentration. The ascorbate cant. This study conformed to the ARVO Resolution ratio of the flow coefficient (kfa) to the diffusion coef- on the Use of Animals in Research. ficient (kdpa) was calculated from the Kinsey-Palm formula," where under steady state conditions: Results = (d X C " C )/(C - C ) a p h a (0 Intravitreal injection of demeclocycline in rabbits where d is the Donnan factor, C the ascorbate con- resulted in a dose-dependent decrease in IOP (Fig. 1). centration in the anterior chamber (Ca) or posterior At the 0.1 mg dose, a statistically significant decrease Downloaded from iovs.arvojournals.org on 09/25/2021 1596 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE / July 1989 Vol. 30 mg%) compared to control eyes (anterior chamber ascorbate = 23.2 ± 1.8 mg%, posterior chamber = 31.8 ± 2.3 mg%). The significant (P < 0.005) de- crease in the ratio and the increase in the concentra- tion of posterior chamber ascorbate are consistent with a decreased entry of water into the eye.
Load more

Recommended publications
  • DDAVP Nasal Spray Is Provided As an Aqueous Solution for Intranasal Use
    DDAVP® Nasal Spray (desmopressin acetate) Rx only DESCRIPTION DDAVP® Nasal Spray (desmopressin acetate) is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. It is chemically defined as follows: Mol. wt. 1183.34 Empirical formula: C46H64N14O12S2•C2H4O2•3H2O 1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate. DDAVP Nasal Spray is provided as an aqueous solution for intranasal use. Each mL contains: Desmopressin acetate 0.1 mg Sodium Chloride 7.5 mg Citric acid monohydrate 1.7 mg Disodium phosphate dihydrate 3.0 mg Benzalkonium chloride solution (50%) 0.2 mg The DDAVP Nasal Spray compression pump delivers 0.1 mL (10 mcg) of DDAVP (desmopressin acetate) per spray. CLINICAL PHARMACOLOGY DDAVP contains as active substance desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. One mL (0.1 mg) of intranasal DDAVP has an antidiuretic activity of about 400 IU; 10 mcg of desmopressin acetate is equivalent to 40 IU. 1. The biphasic half-lives for intranasal DDAVP were 7.8 and 75.5 minutes for the fast and slow phases, compared with 2.5 and 14.5 minutes for lysine vasopressin, another form of the hormone used in this condition. As a result, intranasal DDAVP provides a prompt onset of antidiuretic action with a long duration after each administration. 1 2. The change in structure of arginine vasopressin to DDAVP has resulted in a decreased vasopressor action and decreased actions on visceral smooth muscle relative to the enhanced antidiuretic activity, so that clinically effective antidiuretic doses are usually below threshold levels for effects on vascular or visceral smooth muscle.
    [Show full text]
  • Antibiotic Assay Medium No. 3 (Assay Broth) Is Used for Microbiological Assay of Antibiotics. M042
    HiMedia Laboratories Technical Data Antibiotic Assay Medium No. 3 (Assay Broth) is used for M042 microbiological assay of antibiotics. Antibiotic Assay Medium No. 3 (Assay Broth) is used for microbiological assay of antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 5.000 Beef extract 1.500 Yeast extract 1.500 Dextrose 1.000 Sodium chloride 3.500 Dipotassium phosphate 3.680 Potassium dihydrogen phosphate 1.320 Final pH ( at 25°C) 7.0±0.2 **Formula adjusted, standardized to suit performance parameters Directions Suspend 17.5 grams in 1000 ml distilled water. Heat if necessary to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Advice:Recommended for the Microbiological assay of Amikacin, Bacitracin, Capreomycin, Chlortetracycline,Chloramphenicol,Cycloserine,Demeclocycline,Dihydrostreptomycin, Doxycycline, Gentamicin, Gramicidin, Kanamycin, Methacycline, Neomycin, Novobiocin, Oxytetracycline, Rolitetracycline, Streptomycin, Tetracycline, Tobramycin, Trolendomycin and Tylosin according to official methods . Principle And Interpretation Antibiotic Assay Medium is used in the performance of antibiotic assays. Grove and Randall have elucidated those antibiotic assays and media in their comprehensive treatise on antibiotic assays (1). Antibiotic Assay Medium No. 3 (Assay Broth) is used in the microbiological assay of different antibiotics in pharmaceutical and food products by the turbidimetric method. Ripperre et al reported that turbidimetric methods for determining the potency of antibiotics are inherently more accurate and more precise than agar diffusion procedures (2). Turbidimetric antibiotic assay is based on the change or inhibition of growth of a test microorganims in a liquid medium containing a uniform concentration of an antibiotic. After incubation of the test organism in the working dilutions of the antibiotics, the amount of growth is determined by measuring the light transmittance using spectrophotometer.
    [Show full text]
  • Spray Desmopressin Acetate Nasal Spray 10 Μg/Spray
    PRODUCT MONOGRAPH Pr DDAVP® Spray Desmopressin Acetate Nasal Spray 10 µg/spray Pr DDAVP® Rhinyle Desmopressin Acetate Nasal Solution 0.1 mg/mL Antidiuretic Ferring Inc. Date of Revision: 200 Yorkland Blvd, Suite 800 June 19, 2008 North York, Ontario M2J 5C1 Submission Control No: 119073 DDAVP® Spray and Rhinyle Page 1 of 23 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS....................................................................................................6 DRUG INTERACTIONS ....................................................................................................7 DOSAGE AND ADMINISTRATION................................................................................7 OVERDOSAGE ..................................................................................................................9 ACTION AND CLINICAL PHARMACOLOGY ..............................................................9 STORAGE AND STABILITY..........................................................................................11 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................11 PART II: SCIENTIFIC INFORMATION
    [Show full text]
  • Antibacterial Residue Excretion Via Urine As an Indicator for Therapeutical Treatment Choice and Farm Waste Treatment
    antibiotics Article Antibacterial Residue Excretion via Urine as an Indicator for Therapeutical Treatment Choice and Farm Waste Treatment María Jesús Serrano 1, Diego García-Gonzalo 1 , Eunate Abilleira 2, Janire Elorduy 2, Olga Mitjana 1 , María Victoria Falceto 1, Alicia Laborda 1, Cristina Bonastre 1 , Luis Mata 3 , Santiago Condón 1 and Rafael Pagán 1,* 1 Instituto Agroalimentario de Aragón-IA2, Universidad de Zaragoza-CITA, 50013 Zaragoza, Spain; [email protected] (M.J.S.); [email protected] (D.G.-G.); [email protected] (O.M.); [email protected] (M.V.F.); [email protected] (A.L.); [email protected] (C.B.); [email protected] (S.C.) 2 Public Health Laboratory, Office of Public Health and Addictions, Ministry of Health of the Basque Government, 48160 Derio, Spain; [email protected] (E.A.); [email protected] (J.E.) 3 Department of R&D, ZEULAB S.L., 50197 Zaragoza, Spain; [email protected] * Correspondence: [email protected]; Tel.: +34-9-7676-2675 Abstract: Many of the infectious diseases that affect livestock have bacteria as etiological agents. Thus, therapy is based on antimicrobials that leave the animal’s tissues mainly via urine, reaching the environment through slurry and waste water. Once there, antimicrobial residues may lead to antibacterial resistance as well as toxicity for plants, animals, or humans. Hence, the objective was to describe the rate of antimicrobial excretion in urine in order to select the most appropriate molecule while reducing harmful effects. Thus, 62 pigs were treated with sulfamethoxypyridazine, Citation: Serrano, M.J.; oxytetracycline, and enrofloxacin. Urine was collected through the withdrawal period and analysed García-Gonzalo, D.; Abilleira, E.; via LC-MS/MS.
    [Show full text]
  • Oxytocin Regulates the Expression of Aquaporin 5 in the Latepregnant Rat
    RESEARCH ARTICLE Molecular Reproduction & Development 81:524–530 (2014) Oxytocin Regulates the Expression of Aquaporin 5 in the Late-Pregnant Rat Uterus ESZTER DUCZA,* ADRIENN B. SERES, JUDIT HAJAGOS-TOTH, GEORGE FALKAY, AND ROBERT GASPAR Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary SUMMARY Aquaporins (AQPs) are integral membrane channels responsible for the transport of water across a cell membrane. Based on reports that AQPs are present and accumulate in the female reproductive tract late in pregnancy, our aim was to study the expression of AQP isoforms (AQP1, 2, 3, 5, 8, and 9) at the end of pregnancy in rat in order to determine if they play a role in parturition. Reverse-transcriptase PCR revealed that specific Aqp mRNAs were detectable in the myometrium of non- pregnant and late-pregnancy (Days 18, 20, 21, and 22 of pregnancy) rat uteri. The expression of Aqp5 mRNA and protein were most pronounced on Days 18À21, and were dramatically decreased on Day 22 of pregnancy. In contrast, a significant increase was found in the level of Aqp5 transcript in whole-blood samples ÃCorresponding author: on the last day of pregnancy.The effect of oxytocin on myometrial Aqp5 expression in Department of Pharmacodynamics an organ bath was also investigated. The level of Aqp5 mRNA significantly decreased and Biopharmacy À8 University of Szeged, H-6720 5 min after oxytocin (10 M) administration, similarly to its profile on the day of Eotv€ os€ u. 6, Szeged 6270 delivery; this effect was sensitive to the oxytocin antagonist atosiban. The vasopres- Hungary.
    [Show full text]
  • Management and Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus
    REVIEW Management and treatment of lithium- induced nephrogenic diabetes insipidus Christopher K Finch†, Lithium carbonate is a well documented cause of nephrogenic diabetes insipidus, with as Tyson WA Brooks, many as 10 to 15% of patients taking lithium developing this condition. Clinicians have Peggy Yam & Kristi W Kelley been well aware of lithium toxicity for many years; however, the treatment of this drug- induced condition has generally been remedied by discontinuation of the medication or a †Author for correspondence Methodist University reduction in dose. For those patients unresponsive to traditional treatment measures, Hospital, Department several pharmacotherapeutic regimens have been documented as being effective for the of Pharmacy, University of management of lithium-induced diabetes insipidus including hydrochlorothiazide, Tennessee, College of Pharmacy, 1265 Union Ave., amiloride, indomethacin, desmopressin and correction of serum lithium levels. Memphis, TN 38104, USA Tel.: +1 901 516 2954 Fax: +1 901 516 8178 [email protected] Lithium carbonate is well known for its wide use associated with a mutation(s) of vasopressin in bipolar disorders due to its mood stabilizing receptors. Acquired causes are tubulointerstitial properties. It is also employed in aggression dis- disease (e.g., sickle cell disease, amyloidosis, orders, post-traumatic stress disorders, conduct obstructive uropathy), electrolyte disorders (e.g., disorders and even as adjunctive therapy in hypokalemia and hypercalcemia), pregnancy, or depression. Lithium has many well documented conditions induced by a drug (e.g., lithium, adverse effects as well as a relatively narrow ther- demeclocycline, amphotericin B and apeutic range of 0.4 to 0.8 mmol/l. Clinically vincristine) [3,4]. Lithium is the most common significant adverse effects include polyuria, mus- cause of drug-induced nephrogenic DI [5].
    [Show full text]
  • Vasopressin V2 Is a Promiscuous G Protein-Coupled Receptor That Is Biased by Its Peptide Ligands
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.28.427950; this version posted January 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Vasopressin V2 is a promiscuous G protein-coupled receptor that is biased by its peptide ligands. Franziska M. Heydenreich1,2,3*, Bianca Plouffe2,4, Aurélien Rizk1, Dalibor Milić1,5, Joris Zhou2, Billy Breton2, Christian Le Gouill2, Asuka Inoue6, Michel Bouvier2,* and Dmitry B. Veprintsev1,7,8,* 1Laboratory of Biomolecular Research, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland and Department of Biology, ETH Zürich, 8093 Zürich, Switzerland 2Department of Biochemistry and Molecular medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada 3Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA 4The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, United Kingdom 5Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Campus-Vienna-Biocenter 5, 1030 Vienna, Austria 6Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan. 7Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK. 8Division of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, NG7 2UH, UK. *Correspondence should be addressed to: [email protected], [email protected], [email protected].
    [Show full text]
  • Demeclocycline
    PATIENT & CAREGIVER EDUCATION Demeclocycline This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. What is this drug used for? It is used to treat bacterial infections. It may be given to you for other reasons. Talk with the doctor. What do I need to tell my doctor BEFORE I take this drug? If you have an allergy to demeclocycline or any other part of this drug. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you are taking penicillin. If you are breast-feeding or plan to breast-feed. This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs Demeclocycline 1/8 (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. What are some things I need to know or do while I take this drug? Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists. Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.
    [Show full text]
  • TETRACYCLINES and CHLORAMPHENICOL Protein Synthesis
    ANTIMICROBIALS INHIBITING PROTEIN SYNTHESIS AMINOGLYCOSIDES MACROLIDES TETRACYCLINES AND CHLORAMPHENICOL Protein synthesis Aminoglycosides 1. Aminoglycosides are group of natural and semi -synthetic antibiotics. They have polybasic amino groups linked glycosidically to two or more aminosugar like: sterptidine, 2-deoxy streptamine, glucosamine 2. Aminoglycosides which are derived from: Streptomyces genus are named with the suffix –mycin. While those which are derived from Micromonospora are named with the suffix –micin. Classification of Aminoglycosides 1. Systemic aminogycosides Streptomycin (Streptomyces griseus) Gentamicin (Micromonospora purpurea) Kanamycin (S. kanamyceticus) Tobramycin (S. tenebrarius) Amikacin (Semisynthetic derivative of Kanamycin) Sisomicin (Micromonospora inyoensis) Netilmicin (Semisynthetic derivative of Sisomicin) 2. Topical aminoglycosides Neomycin (S. fradiae) Framycetin (S. lavendulae) Pharmacology of Streptomycin NH H2N NH HO OH Streptidine OH NH H2N O O NH CHO L-Streptose CH3 OH O HO O HO NHCH3 N-Methyl-L- Glucosamine OH Streptomycin Biological Source It is a oldest aminoglycoside antibiotic obtained from Streptomyces griseus. Antibacterial spectrum 1. It is mostly active against gram negative bacteria like H. ducreyi, Brucella, Yersinia pestis, Francisella tularensis, Nocardia,etc. 2. It is also used against M.tuberculosis 3. Few strains of E.coli, V. cholerae, H. influenzae , Enterococci etc. are sensitive at higher concentration. Mechanism of action Aminoglycosides bind to the 16S rRNA of the 30S subunit and inhibit protein synthesis. 1. Transport of aminoglycoside through cell wall and cytoplasmic membrane. a) Diffuse across cell wall of gram negative bacteria by porin channels. b) Transport across cell membrane by carrier mediated process liked with electron transport chain 2. Binding to ribosome resulting in inhibition of protein synthesis A.
    [Show full text]
  • Oral Desmopressin in Central Diabetes Insipidus
    Arch Dis Child: first published as 10.1136/adc.61.3.247 on 1 March 1986. Downloaded from Archives of Disease in Childhood, 1986, 61, 247-250 Oral desmopressin in central diabetes insipidus U WESTGREN, C WITTSTROM, AND A S HARRIS Department of Pediatrics, University Hospital, Lund, and Faculty of Pharmacy, Biomedicum, Uppsala, Sweden SUMMARY Seven paediatric patients with central diabetes insipidus were studied in an open dose ranging study in hospital followed by a six month study on an outpatient basis to assess the efficacy and safety of peroral administration of DDAVP (desmopressin) tablets. In the dose ranging study a dose dependent antidiuretic response was observed. The response to 12-5-50 mcg was, however, less effective in correcting baseline polyuria than were doses of 100 mcg and above. Patients were discharged from hospital on a preliminary dosage regimen ranging from 100 to 400 mcg three times daily. After an initial adjustment in dosage in three patients at one week follow up, all patients were stabilised on treatment with tablets and reported an adequate water turnover at six months. As with the intranasal route of administration dosage requirements varied from patient to patient, and a dose range rather than standard doses were required. A significant correlation, however, was found for the relation between previous intranasal and present oral daily dosage. No adver-se reactions were reported. No clinically significant changes were noted in blood chemistry and urinalysis. All patients expressed a preference for the oral over existing intranasal copyright. treatment. Treatment with tablets offers a beneficial alternative to the intranasal route, particularly in patients with chronic rhinitis or impaired vision.
    [Show full text]
  • Demeclocycline in the Treatment of the Syndrome of Inappropriate Secretion of Antidiuretic Hormone
    Thorax: first published as 10.1136/thx.34.3.324 on 1 June 1979. Downloaded from Thorax, 1979, 34, 324-327 Demeclocycline in the treatment of the syndrome of inappropriate secretion of antidiuretic hormone W H PERKS, E H WALTERS,' I P TAMS, AND K PROWSE From the Department of Respiratory Physiology, City General Hospital, Stoke-on-Trent, Staffordshire, UK ABSTRACT Fourteen patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) have been treated with demethylchlortetracycline (demeclocycline) 1200 mg daily. In 12 patients the underlying lesion was malignant. The serum sodium returned to normal (> 135 mmol/l) in all patients after a mean of 8-6 days (SD+5-3 days). Blood urea rose significantly from the pretreatment level of 4-2±2-3 mmol/l to 10-1±5-1 mmol/l at ten days (p<0 001). The average maximum blood urea was 13-4-6-8 mmol/l. In four patients the urea rose above 20 mmol/l, and in two of these demecyocycline was discontinued because of this rise. The azotaemia could be attributed to a combination of increased urea production and a mild specific drug-induced nephrotoxicity. Discontinuation of demeclocycline in six patients led to a fall in serum sodium, in one case precipitously, and return of the urea towards normal levels. Demeclocycline appears therefore to be an effective maintenance treatment of SIADH, and the azotaemia that occurs is reversible and probably dose dependent. The syndrome of inappropriate secretion of anti- Methods http://thorax.bmj.com/ diuretic hormone (SIADH) has become increas- ingly recognised as a treatable cause of stupor and Fourteen patients with a diagnosis of SIADH confusion in patients with a wide variety of based on the criteria of De Troyer and Demanet diseases (De Troyer and Demanet, 1976).
    [Show full text]
  • RECEPTOR ANTAGONISTS Vasopressin V2 Receptor Antagonists
    1 RECEPTOR ANTAGONISTS Vasopressin V2 receptor antagonists J G Verbalis 232 Building D, Division of Endocrinology and Metabolism, Georgetown University School of Medicine, 4000 Reservoir Road NW, Washington DC 20007, USA (Requests for offprints should be addressed toJGVerbalis; Email: [email protected]) Abstract Hyponatremia, whether due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) or disorders of water retention such as congestive heart failure and cirrhosis, is a very common problem encountered in the care of medical patients. To date, available treatment modalities for disorders of excess arginine vasopressin (AVP) secretion or action have been limited and suboptimal. The recent discovery and development of nonpeptide AVP V2 receptor antagonists represents a promising new treatment option to directly antagonize the effects of elevated plasma AVP concentrations at the level of the renal collecting ducts. By decreasing the water permeability of renal collecting tubules, excretion of retained water is promoted, thereby normalizing or improving hypo-osmolar hyponatremia. In this review, SIADH and other water retaining disorders are briefly discussed, after which the published preclinical and clinical studies of several nonpeptide AVP V2 receptor antagonists are summarized. The likely therapeutic indications and potential complications of these compounds are also described. Journal of Molecular Endocrinology (2002) 29, 1–9 Introduction heart failure (CHF) and cirrhosis with ascites. In these disorders, a relatively decreased intravascular Arginine vasopressin (AVP), the ‘antidiuretic volume and/or pressure leads to water retention as a hormone,’ is the major physiological regulator of result of both decreased distal delivery of glomerular renal free water excretion. Increased AVP secretion filtrate and secondarily elevated plasma AVP levels.
    [Show full text]